X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3466) 3466
Publication (463) 463
Book Review (299) 299
Book Chapter (14) 14
Conference Proceeding (10) 10
Book / eBook (3) 3
Magazine Article (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3382) 3382
animals (3108) 3108
neurosciences (2035) 2035
oligodendroglia - drug effects (1807) 1807
rats (1730) 1730
oligodendroglia - metabolism (1534) 1534
cells, cultured (1326) 1326
mice (1146) 1146
oligodendroglia - cytology (1144) 1144
humans (1047) 1047
central-nervous-system (905) 905
oligodendrocytes (783) 783
oligodendroglia - physiology (718) 718
male (668) 668
female (661) 661
rats, sprague-dawley (642) 642
cell differentiation - drug effects (634) 634
animals, newborn (596) 596
oligodendroglia - pathology (586) 586
oligodendrocyte (577) 577
multiple-sclerosis (571) 571
brain (569) 569
differentiation (494) 494
stem cells - drug effects (494) 494
myelin (482) 482
multiple sclerosis (474) 474
disease models, animal (453) 453
biochemistry & molecular biology (419) 419
immunohistochemistry (419) 419
mice, inbred c57bl (419) 419
myelination (415) 415
neurons (409) 409
neurology (401) 401
myelin sheath - metabolism (398) 398
article (390) 390
expression (388) 388
nervous system (377) 377
stem cells - cytology (372) 372
cell biology (364) 364
apoptosis (362) 362
progenitor cells (362) 362
cell differentiation - physiology (359) 359
astrocytes (356) 356
remyelination (338) 338
analysis (327) 327
demyelination (325) 325
stem cells - metabolism (315) 315
oligodendroglia (309) 309
cells (308) 308
astrocytes - metabolism (307) 307
cell differentiation (307) 307
astrocytes - drug effects (306) 306
in-vitro (302) 302
time factors (293) 293
rats, wistar (283) 283
myelin sheath - drug effects (282) 282
neurons - metabolism (266) 266
myelin basic protein - metabolism (265) 265
neurons - drug effects (265) 265
experimental autoimmune encephalomyelitis (261) 261
research (261) 261
cell line (257) 257
cell survival - drug effects (257) 257
brain - cytology (256) 256
nerve tissue proteins - metabolism (251) 251
spinal-cord (250) 250
mice, transgenic (243) 243
brain - metabolism (240) 240
myelin sheath - physiology (240) 240
stem cells (240) 240
clinical neurology (236) 236
gene-expression (234) 234
dose-response relationship, drug (232) 232
rodents (230) 230
stem cells - physiology (229) 229
gene expression (224) 224
proteins (223) 223
apoptosis - drug effects (219) 219
astrocytes - cytology (219) 219
white-matter (219) 219
central nervous system (216) 216
cell proliferation - drug effects (215) 215
neurons - cytology (214) 214
rat-brain (214) 214
proliferation (212) 212
physiological aspects (211) 211
oligodendroglia - ultrastructure (202) 202
oxidative stress (198) 198
precursor cells (197) 197
signal transduction - drug effects (197) 197
brain - drug effects (195) 195
brain - pathology (195) 195
demyelinating diseases - pathology (192) 192
microglia (190) 190
signal transduction (188) 188
rna, messenger - metabolism (187) 187
myelin proteins (185) 185
cell division - drug effects (183) 183
multidisciplinary sciences (181) 181
growth-factor (180) 180
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3435) 3435
Chinese (12) 12
German (8) 8
Japanese (8) 8
French (5) 5
Russian (3) 3
Spanish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 06/2015, Volume 522, Issue 7555, pp. 216 - 220
Multiple sclerosis involves an aberrant autoimmune response and progressive failure of remyelination in the central nervous system. Prevention of neural... 
MYELIN BASIC-PROTEIN | TRANSCRIPTS | GLUCOCORTICOIDS | MULTIPLE-SCLEROSIS | LYSOLECITHIN | RNA-SEQ | MULTIDISCIPLINARY SCIENCES | SPINAL-CORD | CENTRAL-NERVOUS-SYSTEM | DIFFERENTIATION | OLIGODENDROCYTE PROGENITOR CELLS | Oligodendroglia - metabolism | Encephalomyelitis, Autoimmune, Experimental - metabolism | Humans | Cerebellum - drug effects | Myelin Sheath - drug effects | Male | Receptors, Glucocorticoid - metabolism | Demyelinating Diseases - metabolism | MAP Kinase Signaling System | Myelin Sheath - metabolism | Oligodendroglia - drug effects | Female | Oligodendroglia - cytology | Demyelinating Diseases - pathology | Demyelinating Diseases - drug therapy | Disease Models, Animal | Multiple Sclerosis - metabolism | Germ Layers - drug effects | Germ Layers - pathology | Encephalomyelitis, Autoimmune, Experimental - pathology | Lysophosphatidylcholines | Pluripotent Stem Cells - cytology | Germ Layers - metabolism | Tissue Culture Techniques | Cerebellum - metabolism | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Cerebellum - pathology | Pluripotent Stem Cells - metabolism | Phenotype | Regeneration - drug effects | Animals | Cell Differentiation - drug effects | Miconazole - pharmacology | Pluripotent Stem Cells - drug effects | Multiple Sclerosis - pathology | Mice | Clobetasol - pharmacology | Mitogen-Activated Protein Kinases - metabolism | Multiple Sclerosis - drug therapy | Medical research | Myelination | Multiple sclerosis | Stem cells | Physiological aspects | Medicine, Experimental | Research | Drugs | Proteins | Blood-brain barrier | Laboratories | Rodents | Clinical trials | FDA approval | Gene expression | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 2013, Volume 502, Issue 7471, pp. 327 - 332
Progressive phases of multiple sclerosis are associated with inhibited differentiation of the progenitor cell population that generates the mature... 
OLIGODENDROCYTE DIFFERENTIATION | PROGENITOR CELLS | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | MUSCARINIC RECEPTOR SUBTYPES | THYROID-HORMONE | MYELIN REPAIR | MULTIDISCIPLINARY SCIENCES | EMBRYONIC STEM-CELLS | SPINAL-CORD | CENTRAL-NERVOUS-SYSTEM | PRECURSOR CELLS | Cuprizone - therapeutic use | Oligodendroglia - metabolism | Optic Nerve - cytology | Recurrence | Antiparkinson Agents - pharmacology | Coculture Techniques | Myelin Sheath - drug effects | Receptor, Muscarinic M1 - antagonists & inhibitors | Stem Cells - cytology | Myelin Proteolipid Protein - pharmacology | Myelin Sheath - metabolism | Antiparkinson Agents - therapeutic use | Oligodendroglia - drug effects | Cuprizone - pharmacology | Encephalomyelitis, Autoimmune, Experimental - chemically induced | Propylene Glycols - therapeutic use | Immune System - immunology | Female | Oligodendroglia - cytology | Benztropine - therapeutic use | Propylene Glycols - pharmacology | Encephalomyelitis, Autoimmune, Experimental - pathology | Myelin Sheath - pathology | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Mice, Inbred C57BL | Receptor, Muscarinic M3 - metabolism | Fingolimod Hydrochloride | Rats | Receptor, Muscarinic M3 - antagonists & inhibitors | Oligodendroglia - pathology | Sphingosine - pharmacology | Regeneration - drug effects | Sphingosine - analogs & derivatives | Animals | Cell Differentiation - drug effects | Models, Biological | Immune System - drug effects | Multiple Sclerosis - pathology | Stem Cells - drug effects | Sphingosine - therapeutic use | Mice | Benztropine - pharmacology | Receptor, Muscarinic M1 - metabolism | Multiple Sclerosis - drug therapy | Benztropine | Multiple sclerosis | Myelination | Physiological aspects | Oligodendroglia | Dosage and administration | Drug therapy | Cell differentiation | Cell culture | Dopamine | Drug dosages | Rodents | Cell cycle | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 506, Issue 7487, pp. 230 - 234
There are no clinically relevant treatments available that improve function in the growing population of very preterm infants (less than 32 weeks' gestation)... 
MULTIPLE-SCLEROSIS | LOW-BIRTH-WEIGHT | OLIGODENDROCYTE PROGENITORS | MULTIDISCIPLINARY SCIENCES | HYPOXIC INJURY | CENTRAL-NERVOUS-SYSTEM | MOUSE CORPUS-CALLOSUM | PRETERM INFANTS | RAT-BRAIN | WHITE-MATTER ABNORMALITIES | FACTOR RECEPTOR | Epidermal Growth Factor - administration & dosage | Oligodendroglia - metabolism | Receptor, Epidermal Growth Factor - genetics | Demyelinating Diseases - congenital | Brain Injuries - drug therapy | Humans | Brain Injuries - congenital | Male | Stem Cells - cytology | Demyelinating Diseases - metabolism | Epidermal Growth Factor - therapeutic use | Molecular Targeted Therapy | Stem Cells - metabolism | Cell Lineage - drug effects | Hypoxia - metabolism | Receptor, Epidermal Growth Factor - metabolism | Oligodendroglia - drug effects | Time Factors | Oligodendroglia - cytology | Demyelinating Diseases - pathology | Disease Models, Animal | Animals, Newborn | Cell Survival - drug effects | Demyelinating Diseases - prevention & control | Administration, Intranasal | Infant, Premature, Diseases - drug therapy | Cell Division - drug effects | Brain Injuries - prevention & control | Oligodendroglia - pathology | Hypoxia - genetics | Regeneration - drug effects | Animals | Signal Transduction - drug effects | Cell Differentiation - drug effects | Hypoxia - pathology | Stem Cells - drug effects | Hypoxia - physiopathology | Infant, Premature, Diseases - metabolism | Mice | Epidermal Growth Factor - pharmacology | Brain Injuries - pathology | Infant, Premature, Diseases - pathology | Brain | Medical research | Care and treatment | Infants (Premature) | Risk factors | Complications and side effects | Epidermal growth factor | Physiological aspects | Medicine, Experimental | Hypoxia | Diagnosis | Health aspects | Injuries | Attention deficit disorder | Brain damage | Rodents | Apoptosis | Index Medicus
Journal Article
Journal Article
Annals of Neurology, ISSN 0364-5134, 01/2008, Volume 63, Issue 1, pp. 61 - 71
Objective: FTY720, a sphingosine-1-phosphate (S1P) receptor agonist that crosses the blood-brain barrier, is a potential immuno-therapy for multiple sclerosis.... 
SIGNAL-TRANSDUCTION | CELLS | 1-PHOSPHATE RECEPTOR AGONIST | MULTIPLE-SCLEROSIS | LYSOPHOSPHATIDIC ACID | PROCESS RETRACTION | SUBCORTICAL WHITE-MATTER | COUPLED RECEPTORS | G-PROTEIN | NEUROSCIENCES | CLINICAL NEUROLOGY | SPHINGOSINE 1-PHOSPHATE | Lysophospholipids - metabolism | Oligodendroglia - metabolism | Extracellular Signal-Regulated MAP Kinases - drug effects | Receptors, G-Protein-Coupled - metabolism | Humans | Extracellular Signal-Regulated MAP Kinases - metabolism | RNA, Messenger - metabolism | Stem Cells - metabolism | Cell Movement - physiology | rho-Associated Kinases - antagonists & inhibitors | Oligodendroglia - drug effects | rho-Associated Kinases - metabolism | Propylene Glycols - therapeutic use | Receptors, Lysosphingolipid - genetics | Sphingosine - metabolism | Receptors, G-Protein-Coupled - drug effects | Receptors, Lysosphingolipid - metabolism | Cell Differentiation - physiology | Immunosuppressive Agents - pharmacology | Cell Survival - physiology | Suramin - pharmacology | RNA, Messenger - drug effects | Propylene Glycols - pharmacology | Cell Line | Cell Survival - drug effects | Fingolimod Hydrochloride | Down-Regulation - drug effects | Down-Regulation - genetics | Sphingosine - pharmacology | Cell Movement - drug effects | Sphingosine - analogs & derivatives | Signal Transduction - drug effects | Cell Differentiation - drug effects | Cell Surface Extensions - drug effects | Cytoskeleton - metabolism | Receptors, Lysosphingolipid - agonists | Stem Cells - drug effects | Signal Transduction - physiology | Sphingosine - therapeutic use | Cytoskeleton - drug effects | Index Medicus
Journal Article
Nature Neuroscience, ISSN 1097-6256, 08/2011, Volume 14, Issue 8, pp. 1009 - 1016
Permanent damage to white matter tracts, comprising axons and myelinating oligodendrocytes, is an important component of brain injuries of the newborn that... 
FUNCTIONAL INTERACTION | MULTIPLE-SCLEROSIS | CNS REMYELINATION | MYELINATION | SIGNALING PATHWAY | TRANSCRIPTION | DIFFERENTIATION | BETA-CATENIN | NEUROSCIENCES | WHITE-MATTER INJURY | NEGATIVE REGULATOR | Humans | Ki-67 Antigen - metabolism | Male | Brain Injuries - metabolism | Wnt Proteins - metabolism | Oligodendroglia - drug effects | Hypoxia-Ischemia, Brain - therapy | Infant, Newborn | Organ Culture Techniques | Disease Models, Animal | Animals, Newborn | Basic Helix-Loop-Helix Transcription Factors - genetics | Mice, Transgenic | Oligodendrocyte Transcription Factor 2 | Brain Injuries - therapy | Multiple Sclerosis - therapy | Myelin Proteins - genetics | beta Catenin - metabolism | Heterocyclic Compounds, 3-Ring - therapeutic use | Spinal Cord - physiology | Axin Protein | Mice | Myelin Sheath - ultrastructure | beta-Galactosidase - genetics | Cerebellum - ultrastructure | Myelin Proteins - metabolism | Corpus Callosum - metabolism | Spinal Cord - drug effects | Heterocyclic Compounds, 3-Ring - pharmacology | Myelin Proteins - therapeutic use | Cerebellum - drug effects | Myelin Sheath - drug effects | Hypoxia-Ischemia, Brain - pathology | Cerebral Cortex - cytology | Cytoskeletal Proteins - deficiency | Dose-Response Relationship, Drug | Oligodendroglia - physiology | Wnt Proteins - genetics | beta-Galactosidase - metabolism | Adult | Cytoskeletal Proteins - metabolism | Female | Demyelinating Diseases - chemically induced | Demyelinating Diseases - pathology | Neurons - drug effects | Cell Differentiation - physiology | Hypoxia-Ischemia, Brain - metabolism | Microscopy, Electron, Transmission | Myelin Sheath - pathology | Gene Expression Regulation - genetics | Cerebellum - metabolism | Cells, Cultured | Gene Expression Regulation - physiology | Corpus Callosum - drug effects | Nerve Tissue Proteins - genetics | beta Catenin - genetics | Multiple Sclerosis - complications | Nerve Tissue Proteins - metabolism | Animals | Cell Differentiation - drug effects | Multiple Sclerosis - pathology | Stem Cells - drug effects | Brain Injuries - etiology | Lysophosphatidylcholines - toxicity | Postmortem Changes | Infants (Newborn) | Brain | Care and treatment | Physiological aspects | Research | Binding proteins | Health aspects | Injuries | Index Medicus
Journal Article
Nature Neuroscience, ISSN 1097-6256, 06/2012, Volume 15, Issue 6, pp. 862 - 870
Mesenchymal stem cells (MSCs) have emerged as a potential therapy for a range of neural insults. In animal models of multiple sclerosis, an autoimmune disease... 
IMMUNE-RESPONSE | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | LIVER-REGENERATION | C-MET | BONE-MARROW | ENDOTHELIAL-CELLS | ENDOGENOUS REPAIR | SPINAL-CORD-INJURY | CENTRAL-NERVOUS-SYSTEM | MET TYROSINE KINASE | NEUROSCIENCES | Proto-Oncogene Proteins c-met - metabolism | Oligodendroglia - metabolism | Spinal Cord - drug effects | Encephalomyelitis, Autoimmune, Experimental - metabolism | Recovery of Function - drug effects | Humans | Culture Media, Conditioned - pharmacology | Neurons - cytology | Stem Cells - cytology | Hepatocyte Growth Factor - pharmacology | Stem Cells - metabolism | Oligodendroglia - drug effects | Spinal Cord - pathology | Female | Neurogenesis - drug effects | Neurons - metabolism | Oligodendroglia - cytology | Neurons - drug effects | Multiple Sclerosis - metabolism | Encephalomyelitis, Autoimmune, Experimental - pathology | Mice, Inbred C57BL | Cells, Cultured | Mesenchymal Stromal Cells - metabolism | Rats | Multiple Sclerosis - therapy | Blotting, Western | Hepatocyte Growth Factor - metabolism | Encephalomyelitis, Autoimmune, Experimental - therapy | Animals | Cell Differentiation - drug effects | Multiple Sclerosis - pathology | Stem Cells - drug effects | Mice | Mesenchymal Stem Cell Transplantation | Physiological aspects | Development and progression | Multiple sclerosis | Research | Growth factors | Stem cells | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 2014, Volume 20, Issue 8, pp. 954 - 960
Journal Article
Nature Neuroscience, ISSN 1097-6256, 09/2013, Volume 16, Issue 9, pp. 1211 - 1218
Journal Article